DOP061 Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.